Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth R Chapman

Showing results (101-110 of 176) with videos related to

Pageof 18
Sort By:
Chest|March 16, 2007
Tiotropium and simplified detection of dynamic hyperinflationArthur F Gelb, Colleen Flynn Taylor, Patricia A McClean, et al.
BMC Pulmonary Medicine|January 21, 2014
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyKenneth R Chapman, Kai-Michael Beeh, Jutta Beier, et al.
Bioimpacts : BI|September 28, 2020
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trialKhalil Ansarin, Ramin Tolouian, Mohammadreza Ardalan, et al.
BMC Clinical Pharmacology|October 6, 2010
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized studyJames M Stocks, Mark L Brantly, Laurene Wang-Smith, et al.
The New England Journal of Medicine|May 17, 2016
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDJadwiga A Wedzicha, Donald Banerji, Kenneth R Chapman, et al.
The Lancet. Respiratory Medicine|January 28, 2014
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyMarc L Decramer, Kenneth R Chapman, Ronald Dahl, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension TrialsShuren Ma, Yong Y Lin, Jerome O Cantor, et al.
American Journal of Respiratory and Critical Care Medicine|June 27, 2017
Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 10, 2018
Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD StudyRobert A Wise, Kenneth R Chapman, Benjamin M Scirica, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2017
Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary DiseaseNicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, et al.
Pageof 18

Showing results (101-110 of 176) with videos related to

Sort By:
Pageof 18
Chest|March 16, 2007
Tiotropium and simplified detection of dynamic hyperinflationArthur F Gelb, Colleen Flynn Taylor, Patricia A McClean, et al.
BMC Pulmonary Medicine|January 21, 2014
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 studyKenneth R Chapman, Kai-Michael Beeh, Jutta Beier, et al.
Bioimpacts : BI|September 28, 2020
Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trialKhalil Ansarin, Ramin Tolouian, Mohammadreza Ardalan, et al.
BMC Clinical Pharmacology|October 6, 2010
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized studyJames M Stocks, Mark L Brantly, Laurene Wang-Smith, et al.
The New England Journal of Medicine|May 17, 2016
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPDJadwiga A Wedzicha, Donald Banerji, Kenneth R Chapman, et al.
The Lancet. Respiratory Medicine|January 28, 2014
Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyMarc L Decramer, Kenneth R Chapman, Ronald Dahl, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|August 30, 2017
The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension TrialsShuren Ma, Yong Y Lin, Jerome O Cantor, et al.
American Journal of Respiratory and Critical Care Medicine|June 27, 2017
Reply: What Should Be the Cutoff Value of Blood Eosinophilia as a Predictor of Inhaled Corticosteroid Responsiveness in Patients with Chronic Obstructive Pulmonary Disease?Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|April 10, 2018
Long-Term Evaluation of the Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with Moderate to Very Severe COPD: Rationale and Design of the ASCENT COPD StudyRobert A Wise, Kenneth R Chapman, Benjamin M Scirica, et al.
American Journal of Respiratory and Critical Care Medicine|November 16, 2017
Reply to Cooper et al.: The Significance of Eosinophilic Inflammation in Chronic Obstructive Pulmonary DiseaseNicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, et al.
Pageof 18